Environmental exposure, obesity, and parkinson's disease: Lessons from fat and old worms

Environmental Health Perspectives

Volumn 119, Issue 1, 2011, Pages 20-28

  Aitlhadj, Layla ^a   Ávila, Daiana Silva ^b   Benedetto, Alexandre ^b   Aschner, Michael ^b   Stürzenbaum, Stephen Richard ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

C. elegans; Heavy metals; Neurodegeneration; Obesity; Parkinson's disease; Serotonin

Indexed keywords

DOPAMINE; HEAVY METAL;

AGING; BLOOD BRAIN BARRIER; CAENORHABDITIS ELEGANS; DIETARY INTAKE; DOPAMINERGIC SYSTEM; ENVIRONMENTAL EXPOSURE; EVIDENCE BASED MEDICINE; FEEDING BEHAVIOR; HUMAN; MEDLINE; METABOLIC DISORDER; NERVE DEGENERATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OBESITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW;

AGE FACTORS; ANIMALS; CAENORHABDITIS ELEGANS; CENTRAL NERVOUS SYSTEM; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; HUMANS; METALS; MODELS, ANIMAL; OBESITY; PARKINSON DISEASE;

CAENORHABDITIS ELEGANS;

EID: 78751524128     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1002522     Document Type: Review

References (145)

1. Afeseh Ngwa H, Kanthasamy A, Anantharam V, Song C, Witte T, Houk R, et al. 2009. Vanadium induces dopamin-ergic neuro toxicity via protein kinase Cdelta dependent oxidative signaling mechanisms: relevance to etiopatho-genesis of Parkinson's disease. Toxicol Appl Pharmacol 240(2):273-285.
2. Aitlhadj L, Stürzenbaum SR. 2010. The use of FUdR can cause prolonged longevity in mutant nematodes. Mech Ageing Dev 131(5):364-365.
3. An JH, Blackwell TK. 2003. SKN-1 links C. elegans mesendo-dermal specification to a conserved oxidative stress response. Genes Dev 17(15):1882-1893.
4. Andersen JK. 2003. Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease. Neurotox Res 5(5):307-313.
5. Aschner M, Guilarte TR, Schneider JS, Zheng W. 2007. Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol 221(2):131-147.
6. Ashraf K. 2007. Obesity and the regulation of fat metabolism Mar 9:1; doi:10.1895/wormbook.1.130.1 [Online 9 March 2007].
7. Ashraf K, Chang FY, Watts JL, Fraser AG, Kamath RS, Ahringer J, et al. 2003. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 421(6920):268-272.
8. Au C, Benedetto A, Anderson J, Labrousse A, Erikson K, Ewbank JJ, et al. 2009. SMF-1, SMF-2 and SMF-3 DMT1 orthologues regulate and are regulated differentially by manganese levels in C. elegans. PLoS One 4(11):e7792; doi:10.1371/journal.pone.0007792 [Online 18 November 2009].
9. Au C, Benedetto A, Aschner M. 2008. Manganese transport in eukaryotes: the role of DMT1. Neurotoxicology 29(4):569-576.
10. Avila-Costa MR, Montiel Flores E, Colin-Barenque L, Ordoñez JL, Gutiérrez AL, Niño-Cabrera HG, et al. 2004. Nigrostriatal modifications after vanadium inhalation: an immuno-cytochemical and cytological approach. Neurochem Res 29(7):1365-1369.
11. Ayyadevara S, Alla R, Thaden JJ, Shmookler Reis RJ. 2008. Remarkable longevity and stress resistance of nematode PI3K-null mutants. Aging Cell 7(1):13-22.
12. Bargmann CI. 1998. Neurobiology of the Caenorhabditis elegans genome. Science 282(5396):2028-2033.
13. Belsare PV, Watve MG, Ghaskadbi SS, Bhat DS, Yajnik CS, Jog M. 2010. Metabolic syndrome: aggression control mechanisms gone out of control. Med Hypotheses 74(3):578-589.
14. Benedetto A, Au C, Aschner M. 2009. Manganese-induced dop-aminergic neurodegeneration: insights into mechanisms and genetics shared with Parkinson's disease. Chem Rev 109(10):4862-4884.
15. Benedetto A, Au C, Avila DS, Milatovic D, Aschner M. 2010. Extracellular dopamine potentiates Mn-induced oxida-tive stress, lifespan reduction and dopaminergic neuro-degeneration in a BLI-3-dependent manner in C. elegans. Plos Genet 6(8):e1001084; doi:10.1371/journal.pgen.1001084 [Online 26 August 2010].
16. Benzinou M, Walley A, Lobbens S, Charles MA, Jouret B, Fumeron F, et al. 2006. Bardet-Biedl syndrome gene variants are associated with both childhood and adult common obesity in French Caucasians. Diabetes 55(10):2876-2882.
17. Bharathi, Ravid R, Rao KS. 2006. Role of metals in neuronal apoptosis: challenges associated with neurodegeneration. Curr Alzheimer Res 3(4):311-326.
18. Braungart E, Gerlach M, Riederer P, Baumeister R, Hoener MC. 2004. Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings. Neurodegener Dis 1(4-5):175-183.
19. Brock CJ, Walker JE. 1980. Superoxide dismutase from Bacillus stearothermophilus. Complete amino acid sequence of a manganese enzyme. Biochemistry 19(13):2873-2882.
20. Burnell AM, Houthoofd K, O'Hanlon K, Vanfleteren JR. 2005. Alternate metabolism during the dauer stage of the nema-tode Caenorhabditis elegans. Exp Gerontol 40(11):850-856.
21. Burton NC, Guilarte TR. 2009. Manganese neurotoxicity: lessons learned from longitudinal studies in nonhuman primates. Environ Health Perspect 117:325-332.
22. Byerly L, Cassada RC, Russell RL. 1976. The life cycle of the nematode Caenorhabditis elegans. I. Wild-type growth and reproduction. Dev Biol 51(1):23-33.
23. C. elegans Sequencing Consortium. 1998. Genome sequence of the nematode C. elegans: a platform for investigating biology. Science 282(5396):2012-2018.
24. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. 1995. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269(5223):546-549.
25. Chang TL, Chang CJ, Lee WY, Lin MN, Huang YW, Fan K. 2009. The roles of ubiquitin and 26S proteasome in human obesity. Metabolism 58(11):1643-1648.
26. Chase DL, Koelle MR. 2007. Biogenic amine neuro transmitters in C. elegans. WormBook Feb 20:1; doi:10.1895/ wormbook. 1.132.1 [Online 20 February 2007].
27. Chatterjee N, Sinha S. 2008. Understanding the mind of a worm: hierarchical network structure underlying nervous system function in C. elegans. Prog Brain Res 168:145-153.
28. Chen JC, Cavallari JM, Stone PH, Christiani DC. 2007. Obesity is a modifer of autonomic cardiac responses to fne metal particulates. Environ Health Perspect 115:1002-1006.
29. Chen HS, Lipton SA. 2006. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 97(6):1611-1626.
30. Chung EY, Yoon JR. 2008. Ketamine potentiates neurotoxicity in obese mice. Korean J Anesthesiol 55(4):473-478.
31. Cory-Slechta DA, Thiruchelvam M, Barlow BK, Richfield EK. 2005. Developmental pesticide models of the Parkinson disease phenotype. Environ Health Perspect 113:1263-1270.
32. Coyle CA, Strand SC, Good DJ. 2008. Reduced activity without hyperphagia contributes to obesity in Tubby mutant mice. Physiol Behav 95(1-2):168-175.
33. Deng X, Cadet JL. 1999. Methamphetamine administration causes overexpression of nNOS in the mouse striatum. Brain Res 851(1-2):254-257.
34. Díaz-Véliz G, Mora S, Gómez P, Dossi MT, Montiel J, Arriagada C, et al. 2004. Behavioral effects of manganese injected in the rat substantia nigra are potentiated by dicumarol, a DT-diaphorase inhibitor. Pharmacol Biochem Behav 77(2):245-251.
35. Dobson AW, Erikson KM, Aschner M. 2004. Manganese neuro-toxicity. Ann NY Acad Sci 1012:115-128.
36. Doherty GH, Oldreive C, Harvey J. 2008. Neuroprotective actions of leptin on central and peripheral neurons in vitro. Neuroscience 154(4):1297-1307.
37. Donohoe DR, Aamodt EJ, Osborn E, Dwyer DS. 2006. Antipsychotic drugs disrupt normal development in Caenorhabditis elegans via additional mechanisms besides dopamine and serotonin receptors. Pharmacol Res 54(5):361-372.
38. Duerr JS, Frisby DL, Gaskin J, Duke A, Asermely K, Huddleston D, et al. 1999. The cat-1 gene of Caenorhabditis elegans encodes a vesicular monoamine transporter required for specific monoamine-dependent behaviors. J Neurosci 19(1):72-84.
39. Edwards TM, Myers JP. 2008. Environmental exposures and gene regulation in disease etiology. Cien Saude Colet 13(1):269-281.
40. Erikson KM, Thompson K, Aschner J, Aschner M. 2007. Manganese neurotoxicity: a focus on the neonate. Pharmacol Ther 113(2):369-377.
41. Figlewicz DP, McDonald Naleid A, Sipols AJ. 2007. Modulation of food reward by adiposity signals. Physiol Behav 91(5):473-478.
42. Gaglia MM, Kenyon C. 2009. Stimulation of movement in a quiescent, hibernation-like form of Caenorhabditis elegans by dopamine signaling. J Neurosci 29(22):7302-7314.
43. Gami MS, Iser WB, Hanselman KB, Wolkow CA. 2006. Activated AKT/PKB signaling in C. elegans uncouples temporally distinct outputs of DAF-2/insulin-like signaling. BMC Dev Biol 6:45; doi:10.1186/1471-213X-6-45 [Online 4 October 2006].
44. Gerlach M, Riederer P. 1996. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103(8-9):987-1041.
45. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, et al. 2009. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 41(3):308-315.
46. Glinka Y, Gassen M, Youdim MB. 1997. Mechanism of 6-hydroxy dopamine neurotoxicity. J Neural Transm Suppl 50:55-66.
47. Grad LI, Lemire BD. 2004. Mitochondrial complex I mutations in Caenorhabditis elegans produce cytochrome c oxidase defciency, oxidative stress and vitamin-responsive lactic acidosis. Hum Mol Genet 13(3):303-314.
48. Graumann R, Paris I, Martinez-Alvarado P, Rumanque P, Perez-Pastene C, Cardenas SP, et al. 2002. Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson's disease. Possible neuroprotective role of DT-diaphorase. Pol J Pharmacol 54(6):573-579.
49. Guilarte TR. 2010. Manganese and Parkinson's disease: a critical review and new fndings. Environ Health Perspect 118:1071-1080.
50. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269(5223):543-546.
51. Hamamichi S, Rivas RN, Knight AL, Cao S, Caldwell KA, Caldwell GA. 2008. Hypothesis-based RNAi screening identifes neuroprotective genes in a Parkinson's disease model. Proc Natl Acad Sci USA 105(2):728-733.
52. Hapiak VM, Hobson RJ, Hughes L, Smith K, Harris G, Condon C, et al. 2009. Dual excitatory and inhibitory serotonergic inputs modulate egg laying in Caenorhabditis elegans. Genetics 181(1):153-163.
53. Heida NM, Müller JP, Cheng IF, Leifheit-Nestler M, Faustin V, Riggert J, et al. 2010. Effects of obesity and weight loss on the functional properties of early outgrowth endothelial progenitor cells. J Am Coll Cardiol 55(4):357-367.
54. Hellerer T, Axäng C, Brackmann C, Hillertz P, Pilon M, Enejder A. 2007. Monitoring of lipid storage in Caenorhabditis elegans using coherent anti-Stokes Raman scattering (CARS) microscopy. Proc Natl Acad Sci USA 104(37):14658-14663.
55. Hills T, Brockie PJ, Maricq AV. 2004. Dopamine and glutamate control area-restricted search behavior in Caenorhabditis elegans. J Neurosci 24(5):1217-1225.
56. Hirata Y. 2002. Manganese-induced apoptosis in PC12 cells. Neurotoxicol Teratol 24(5):639-653.
57. Holson RR, Webb PJ, Grafton TF, Hansen DK. 1994. Prenatal neuroleptic exposure and growth stunting in the rat: an in vivo and in vitro examination of sensitive periods and possible mechanisms. Teratology 50(2):125-136.
58. Holt SJ, Riddle DL. 2003. SAGE surveys C. elegans carbohydrate metabolism: evidence for an anaerobic shift in the long-lived dauer larva. Mech Ageing Dev 124(7):779-800.
59. Horvitz HR, Chalfie M, Trent C, Sulston JE, Evans PD. 1982. Serotonin and octopamine in the nematode Caenorhabditis elegans. Science 216(4549):1012-1014.
60. Hughes SL, Bundy JG, Want EJ, Kille P, Stürzenbaum SR. 2009. The metabolomic responses of Caenorhabditis elegans to cadmium are largely independent of metallothionein status, but dominated by changes in cystathionine and phytochelatins. J Proteome Res 8(7):3512-3519.
61. Inglis PN, Ou G, Leroux MR, Scholey JM. 2006. The sensory cilia of Caenorhabditis elegans. WormBook Nov 27:1; doi:10.1895/wormbook.1.126.1 [Online 27 November 2006].
62. Inoue H, Hisamoto N, An JH, Oliveira RP, Nishida E, Blackwell TK, et al. 2005. The C. elegans p38 MAPK pathway regulates nuclear localization of the transcription factor SKN-1 in oxidative stress response. Genes Dev 19(19):2278-2283.
63. Ishiguro H, Yasuda K, Ishii N, Ihara K, Ohkubo T, Hiyoshi M, et al. 2001. Enhancement of oxidative damage to cultured cells and Caenorhabditis elegans by mitochondrial electron transport inhibitors. IUBMB Life 51(4):263-268.
64. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. 1985. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82(7):2173-2177.
65. Jayanthi LD, Apparsundaram S, Malone MD, Ward E, Miller DM, Eppler M, et al. 1998. The Caenorhabditis elegans gene T23G5.5 encodes an antidepressant- and cocaine-sensitive dopamine transporter. Mol Pharmacol 54(4):601-609.
66. Kalra PS, Dube MG, Xu B, Farmerie WG, Kalra SP. 1998. Evidence that dark-phase hyperphagia induced by neuro-toxin 6-hydroxydopamine may be due to decreased leptin and increased neuropeptide Y signaling. Physiol Behav 63(5):829-835.
67. Kennedy GC. 1953. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond B Biol Sci 140(901):578-596.
68. Kogan FJ, Nichols WK, Gibb JW. 1976. Influence of meth-amphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur J Pharmacol 36(2):363-371.
69. Koh JY. 2001. Zinc and disease of the brain. Mol Neurobiol 24(1-3):99-106.
70. Lant B, Storey KB. 2010. An overview of stress response and hypometabolic strategies in Caenorhabditis elegans: conserved and contrasting signals with the mammalian system. Int J Biol Sci. 2010 Jan 7;6(1):9-50.
71. Lakso M, Vartiainen S, Moilanen AM, Sirvio J, Thomas JH, Nass R, et al. 2003. Dopaminergic neuronal loss and motor defcits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 86(1):165-172.
72. Lints R, Emmons SW. 1999. Patterning of dopaminergic neu-rotransmitter identity among Caenorhabditis elegans ray sensory neurons by a TGFbeta family signaling pathway and a Hox gene. Development 126(24):5819-5831.
73. Loer CM, Kenyon CJ. 1993. Serotonin-deficient mutants and male mating behavior in the nematode Caenorhabditis elegans. J Neurosci 13(12):5407-5417.
74. Lotharius J, Dugan LL, O'Malley KL. 1999. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dop-aminergic neurons. J Neurosci 19(4):1284-1293.
75. Mak HY, Nelson LS, Basson M, Johnson CD, Ruvkun G. 2006. Polygenic control of Caenorhabditis elegans fat storage. Nat Genet 3(3):363-368.
76. Marvanova M, Nichols CD. 2007. Identifcation of neuro protective compounds of Caenorhabditis elegans dopaminergic neurons against 6-OHDA. J Mol Neurosci 31(2):127-137.
77. Marza E, Lesa GM. 2006. Polyunsaturated fatty acids and neuro transmission in Caenorhabditis elegans. Biochem Soc Trans 34(Pt 1):77-80.
78. McDonald PW, Jessen T, Field JR, Blakely RD. 2006. Dopamine signaling architecture in Caenorhabditis elegans. Cell Mol Neurobiol 26(4-6):593-618.
79. McKay RM, McKay JP, Avery L, Graff JM. 2003. C elegans: a model for exploring the genetics of fat storage. Dev Cell 4(1):131-142.
80. McNaught KS, Perl DP, Brownell AL, Olanow CW. 2004. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56(1):149-162.
81. Mizuno Y, Suzuki K, Sone N, Saitoh T. 1988. Inhibition of mito-chondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetra-hydro pyridine (MPTP) in mouse brain in vivo. Neurosci Lett 91(3):349-353.
82. Moroz N, Tong M, Longato L, Xu H, de la Monte SM. 2008. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis 15(1):29-44.
83. Mukhopadhyay A, Deplancke B, Walhout AJ, Tissenbaum HA. 2005. C. elegans tubby regulates life span and fat storage by two independent mechanisms. Cell Metab 2(1):35-42.
84. Mullaney BC, Ashraf K. 2009. C. elegans fat storage and metabolic regulation. Biochim Biophys Acta 1791(6):474-478.
85. Nass R, Hall DH, Miller DM III, Blakely RD. 2002. Neurotoxin-induced degeneration of dopamine neurons in Caenorhab-ditis elegans. Proc Natl Acad Sci USA 99(5):3264-3269.
86. Niacaris T, Avery L. 2003. Serotonin regulates repolariza-tion of the C. elegans pharyngeal muscle. J Exp Biol 206(Pt 2):223-231.
87. Noben-Trauth K, Naggert JK, North MA, Nishina PM. 1996. A candidate gene for the mouse mutation tubby. Nature 380(6574):534-538.
88. Nomura T, Horikawa M, Shimamura S, Hashimoto T, Sakamoto K. 2009. Fat accumulation in Caenorhabditis elegans is mediated by SREBP homolog SBP-1. Genes Nutr 5(1):17-27.
89. Ong WY, Farooqui AA. 2005. Iron, neuroinflammation, and Alzheimer's disease. J Alzheimers Dis 8(2):183-200.
90. Oort PJ, Knotts TA, Grino M, Naour N, Bastard JP, Clément K, et al. 2008. Gamma-synuclein is an adipocyte-neuron gene coordinately expressed with leptin and increased in human obesity. J Nutr 138(5):841-848.
91. O'Rourke EJ, Soukas AA, Carr CE, Ruvkun G. 2009. C. elegans major fats are stored in vesicles distinct from lysosome-related organelles. Cell Metab 10(5):430-435.
92. Palmiter RD. 2007. Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci 30(8):375-381.
93. Pan J, Wang Q, Snell WJ. 2005. Cilium-generated signaling and cilia-related disorders. Lab Invest 85(4):452-463.
94. Pannacciulli N, Del Parigi A, Chen K, Le DS, Reiman EM, Tataranni PA. 2006. Brain abnormalities in human obesity: a voxel-based morphometric study. Neuroimage 31(4):1419-1425.
95. Pu P, Le W. 2008. Dopamine neuron degeneration induced by MPP+ is independent of CED-4 pathway in Caenorhabditis elegans. Cell Res 18(9):978-981.
96. Rand JB, Duerr JS, Frisby DL. 1998. Using Caenorhabditis elegans to study vesicular transport. Methods Enzymol 296:529-547.
97. Rankin CH. 2002. From gene to identifed neuron to behaviour in Caenorhabditis elegans. Nat Rev Genet 3(8):622-630.
98. Roeder T. 2005. Tyramine and octopamine: ruling behavior and metabolism. Annu Rev Entomol 50:447-477.
99. Rommelfanger KS, Weinshenker D. 2007. Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74(2):177-190.
100. Ruan Q, Harrington AJ, Caldwell KA, Caldwell GA, Standaert DG. 2010. VPS41, a protein involved in lyso-somal traffcking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease. Neurobiol Dis 37(2):330-338.
101. Russ H, Staust K, Martel F, Gliese M, Schomig E. 1996. The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia. Eur J Neurosci 8(6):1256-1264.
102. Ryu KY, Garza JC, Lu XY, Barsh GS, Kopito RR. 2008. Hypothalamic neurodegeneration and adult-onset obesity in mice lacking the Ubb polyubiquitin gene. Proc Natl Acad Sci USA 105(10):4016-4021.
103. Sakaguchi-Nakashima A, Meir JY, Jin Y, Matsumoto K, Hisamoto N. 2007. LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr Biol 17(7):592-598.
104. Samad F, Yamamoto K, Pandey M, Loskutoff DJ. 1997. Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med 3(1):37-48.
105. Samann J, Hegermann J, von Gromoff E, Eimer S, Baumeister R, Schmidt E. 2009. Caenorhabditis elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem 284(24):16482-16491.
106. Santagata S, Boggon TJ, Baird CL, Gomez CA, Zhao J, Shan WS, et al. 2001. G-protein signaling through tubby proteins. Science 292(5524):2041-2050.
107. Sawin ER, Ranganathan R, Horvitz HR. 2000. C. elegans loco-motory rate is modulated by the environment through a dopaminergic pathway and by experience through a sero-tonergic pathway. Neuron 26(3):619-631.
108. Schafer WR, Kenyon CJ. 1995. A calcium-channel homologue required for adaptation to dopamine and serotonin in Caenorhabditis elegans. Nature 375(6526):73-78.
109. Schapira AH, Cleeter MW, Muddle JR, Workman JM, Cooper JM, King RH. 2006. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol 60(2):253-255.
110. Settivari R, Levora J, Nass R. 2009. The divalent metal transporter homologues SMF-1/2 mediate dopamine neuron sensitivity in Caenorhabditis elegans models of manganism and Parkinson disease. J Biol Chem 284(51):35758-35768.
111. Shimabukuro M, Koyama K, Lee Y, Unger RH. 1997. Leptin- or troglitazone-induced lipopenia protects islets from inter-leukin 1beta cytotoxicity. J Clin Invest 100(7):1750-1754.
112. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. 2003. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302(5646):841.
113. Sonsalla PK, Nicklas WJ, Heikkila RE. 1989. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243(4889):398-400.
114. Srinivasan S, Sadegh L, Elle IC, Christensen AG, Faergeman NJ, Ashrafi K. 2008. Serotonin regulates C. elegans fat and feeding through independent molecular mechanisms. Cell Metab 7(6):533-544.
115. Sriram K, Benkovic SA, Miller DB, O'Callaghan JP. 2002. Obesity exacerbates chemically induced neurodegeneration. Neuroscience 115(4):1335-1346.
116. Stürzenbaum SR, Andre J, Kille P, Morgan AJ. 2009. Earthworm genomes, genes and proteins: the (re)discovery of Darwin's worms. Proc Biol Sci 276(1658):789-797.
117. Stürzenbaum SR, Winters C, Galay M, Morgan AJ, Kille P. 2001. Metal ion trafficking in earthworms. Identification of a cadmium-specific metallothionein. J Biol Chem 276(36):34013-34018.
118. Sulston JE, Albertson DG, Thomson JN. 1980. The Caenorhabditis elegans male: postembryonic development of nongonadal structures. Dev Biol 78(2):542-576.
119. Sulston J, Dew M, Brenner S. 1975. Dopaminergic neurons in the nematode Caenorhabditis elegans. J Comp Neurol 163(2):215-226.
120. Sulston JE, Horvitz HR. 1977. Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. Dev Biol 56(1):110-156.
121. Takeda Y, Avila H. 1986. Structure and gene expression of the E. coli Mn-superoxide dismutase gene. Nucleic Acids Res 14(11):4577-4589.
122. Taki Y, Kinomura S, Sato K, Inoue K, Goto R, Okada K, et al. 2008. Relationship between body mass index and gray matter volume in 1,428 healthy individuals. Obesity (Silver Spring) 16(1):119-124.
123. Tong YG, Burglin TR. 2010. Conditions for dye-flling of sensory neurons in Caenorhabditis elegans. J Neurosci Methods 188(1):58-61.
124. Trayhurn P, Fuller L. 1980. The development of obesity in geneti cally diabetic-obese (db/db) mice pair-fed with lean siblings. The importance of thermoregulatory thermo-genesis. Diabetologia 19(2):148-153.
125. Tullet JM, Hertweck M, An JH, Baker J, Hwang JY, Liu S, et al. 2008. Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans. Cell 132(6):1025-1038.
126. Turunen AW, Verkasalo PK, Kiviranta H, Pukkala E, Jula A, Mannisto S, et al. 2008. Mortality in a cohort with high fsh consumption. Int J Epidemiol 37(5):1008-1017.
127. Uttara B, Singh AV, Zamboni P, Mahajan RT. 2009. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 7(1):65-74.
128. Van Gilst MR, Hadjivassiliou H, Yamamoto KR. 2005. A Caenorhabditis elegans nutrient response system partially dependent on nuclear receptor NHR-49. Proc Natl Acad Sci USA 102(38):13496-13501.
129. Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, et al. 2005. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 280(52):42655-42668.
130. Voisine C, Varma H, Walker N, Bates EA, Stockwell BR, Hart AC. 2007. Identifcation of potential therapeutic drugs for Huntington's disease using Caenorhabditis elegans. PLoS One 2(6):e504; doi:10.1371/journal.pone.0000504 [Online 6 June 2007].
131. Wang J, Kim SK. 2003. Global analysis of dauer gene expression in Caenorhabditis elegans. Development 130(8):1621-1634.
132. Wang J, Rahman MF, Duhart HM, Newport GD, Patterson TA, Murdock RC, et al. 2009. Expression changes of dop-aminergic system-related genes in PC12 cells induced by manganese, silver, or copper nanoparticles. Neurotoxicology 30(6):926-933.
133. Ward MA, Carlsson CM, Trivedi MA, Sager MA, Johnson SC. 2005. The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study. BMC Neurol 5:23; doi:10.1186/1471-2377-5-23 [Online 2 December 2005].
134. Wedler FC, Denman RB. 1984. Glutamine synthetase: the major Mn(II) enzyme in mammalian brain. Curr Top Cell Regul 24:153-169.
135. Weinshenker D, Garriga G, Thomas JH. 1995. Genetic and pharmacological analysis of neurotransmitters controlling egg laying in C. elegans. J Neurosci 15(10):6975-6985.
136. White JG, Southgate E, Thomson JN, Brenner S. 1986. The structure of the nervous system of the nematode Caenorhabditis elegans. Philos Trans R Soc Lond B Biol Sci 314(1165):1-340.
137. Whittaker AJ, Sternberg PW. 2009. Coordination of opposing sex-specifc and core muscle groups regulates male tail posture during Caenorhabditis elegans male mating behavior. BMC Biol 7:33; doi:10.1186/1741-7007-7-33 [Online 22 June 2009].
138. WHO (World Health Organization). 2010. Obesity and overweight. Available: http://www.who.int/dietphysicalactivity/media/en/gsfs_obesity.pdf [accessed 1 March 2010].
139. Williams G. 2010. Withdrawal of sibutramine in Europe [Editorial]. BMJ 340:c824; doi:10.1136/bmj.c824 [Online 9 February 2010].
140. Wimalasena DS, Wiese TJ, Wimalasena K. 2007. Copper ions disrupt dopamine metabolism via inhibition of V-H+-ATPase: a possible contributing factor to neuro-toxicity. J Neurochem 101(2):313-326.
141. Wintle RF, Van Tol HH. 2001. Dopamine signaling in Caenorhabditis elegans-potential for parkinsonism research. Parkinsonism Relat Disord 7(3):177-183.
142. You YJ, Kim J, Raizen DM, Avery L. 2008. Insulin, cGMP, and TGF-beta signals regulate food intake and quiescence in C. elegans: a model for satiety. Cell Metab 7(3):249-257.
143. 2+) induces degeneration of dopaminergic neurons in the nigrostriatal system of rats. Neurosci Bull 24(2):73-78.
144. Zeitoun-Ghandour S, Charnock JM, Hodson ME, Leszczyszyn OI, Blindauer CA, Stürzenbaum SR. 2010. The two Caenorhabditis elegans metallothioneins (CeMT-1 and CeMT-2) discriminate between essential zinc and toxic cadmium. FEBS J 277(11):2531-2542.
145. Zeng BY, Bukhatwa S, Hikima A, Rose S, Jenner P. 2006. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann Neurol 60(2):248-252.